A new study suggests that a combination of radiation therapy and immune checkpoint inhibitors (ICIs) may offer a less ...
For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was ...
Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...
Studies from Munich University highlighted quality of life in bladder and prostate cancer at ASCO 2025 Genitourinary Cancers ...
Amid a rapidly evolving landscape in the treatment of muscle-invasive bladder cancer (MIBC), new findings presented at the ...
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...
A phase II clinical trial found that combining radiotherapy with immune checkpoint inhibitors (durvalumab and tremelimumab) ...
Researchers led by the University of Ulsan College of Medicine, Korea, have checked the performance of a noninvasive urinary ...
The bladder cancer market is poised for transformative growth between 2025 and 2035, driven by rising global incidence rates, ...
The treatment regimen reduced the risk of developing distant metastases or death due to bladder cancer by 33%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback